Stock comparison
Abbott Laboratories
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 79B | HALO |
| Benjamin Graham | 69B | 83A | HALO |
| Philip Fisher | 46D | 65B | HALO |
| Peter Lynch | 24F | 53D | HALO |
| Joel Greenblatt | 42D | 40D | ABT |
| Charlie Munger | 57C | 80C | HALO |
| Terry Smith | 54D | 84A | HALO |
Side-by-side metrics
| Metric | ABT | HALO |
|---|---|---|
| Market cap | $152.25B | $8.1B |
| P/E (TTM) | 23.5x | 24.0x |
| EV/EBIT | 21.7x | 10.2x |
| ROIC (TTM) | 6.56% | 23.65% |
| Gross margin | 56.38% | 81.24% |
| Net margin | 13.91% | 23.13% |
| Revenue CAGR 5y | 0.72% | 33.23% |
| EPS CAGR 5y | -1.48% | -1.98% |
| Debt / Equity | 0.7x | 1.0x |
| Dividend yield | 2.89% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Dividend yield2.89%vs 0.0%+100%
- Market cap$152.25Bvs $8.1B+95%
- Debt / Equity0.7xvs 1.0x+31%
- EPS CAGR 5y-1.48%vs -1.98%+25%
HALO leads on
- Revenue CAGR 5y33.23%vs 0.72%+98%
- ROIC (TTM)23.65%vs 6.56%+72%
- EV/EBIT10.2xvs 21.7x+53%
- Net margin23.13%vs 13.91%+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.